Anticancer Peptidylarginine Deiminase (PAD) Inhibitors Regulate the Autophagy Flux and the Mammalian Target of Rapamycin Complex 1 Activity*

Yuji Wang†‡§, Pingxin Li†, Shu Wang††, Jing Hu‡, Xiangyun Amy Chen‡, Jianhui Wu‡‖, Megan Fisher‡, Kira Oshaben‡, Na Zhao‡, Ying Gu‡, Dong Wang‡, Gong Chen§, and Yanming Wang†‡

Received for publication, April 25, 2012, and in revised form, May 15, 2012 Published, JBC Papers in Press, May 17, 2012, DOI 10.1074/jbc.M112.375725

From the †Center for Eukaryotic Gene Regulation, Department of Biochemistry and Molecular Biology and ‡Department of Chemistry, Pennsylvania State University, University Park, Pennsylvania 16802, the §College of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, China, and the ¶Department of Statistics, University of Nebraska, Lincoln, Nebraska 68583

** This work was supported, in whole or in part, by National Institutes of Health Grant R01 CA136856 (to Y. M. W.) and supported by a start-up fund from Pennsylvania State University (to G. C.). In addition, the work was made possible by a PSU Clinical and Translation Science Institute Pilot Grant Award (to G. C. and Y. M. W.).

† This article contains supplemental Materials and Methods, Tables S1 and S2, Figs. S1–S9, and Videos S1–S3.

‡ These authors contributed equally to this work.

§ To whom correspondence may be addressed. E-mail: guc11@psu.edu.

‖ To whom correspondence may be addressed. E-mail: yuw12@psu.edu.

Background: Histone citrullination by PAD4 regulates tumor suppressor gene expression.

Results: The novel PAD inhibitor YW3-56 inhibits cancerous growth by perturbing autophagy and regulating the SESN2-mTORC1 signaling axis.

Conclusion: YW3-56 regulates the SESN2-mTORC1 autophagy pathway as one of its anticancer mechanisms.

Significance: This study identifies a novel function of PAD4 in the autophagy pathway and developed potent PAD inhibitors for future cancer research.

Tumor suppressor genes are frequently silenced in cancer cells by enzymes catalyzing epigenetic histone modifications. The peptidylarginine deiminase family member PAD4 (also called PADI4) is markedly overexpressed in a majority of human cancers, suggesting that PAD4 is a putative target for cancer treatment. Here, we have generated novel PAD inhibitors with low micromolar IC₅₀ in PAD activity and cancer cell growth inhibition. The lead compound YW3-56 alters the expression of genes controlling the cell cycle and cell death, including SESN2 that encodes an upstream inhibitor of the mammalian target of rapamycin complex 1 (mTORC1) signaling pathway. Guided by the gene expression profile analyses with YW3-56, we found that PAD4 functions as a co-repressor of p53 to regulate SESN2 expression by histone citrullination in cancer cells. Consistent with the mTORC1 inhibition by SESN2, the phosphorylation of its substrates including p70S6 kinase (p70S6K) and 4E-BP1 was decreased. Furthermore, macroautophagy is perturbed after YW3-56 treatment in cancer cells. In a mouse xenograft model, YW3-56 demonstrates cancer growth inhibition activity with little if any detectable adverse effect to vital organs, whereas a combination of PAD4 and histone deacetylase inhibitors further decreases tumor growth. Taken together, our work found that PAD4 regulates the mTORC1 signaling pathway and that PAD inhibitors are potential anticancer reagents that activate tumor suppressor gene expression alone or in combination with histone deacetylase inhibitors.

In eukaryotic cells, covalent histone modifications play important roles in regulating gene expression during normal development and in disease etiology (1, 2). Notably, aberrant silencing of tumor suppressor genes by epigenetic modifiers has been recognized as an early onset event during tumorigenesis (3–5). Within the last several decades, small molecule inhibitors against DNA methyltransferases and histone deacetylases have been developed as effective reagents to activate tumor suppressor gene expression in cancer chemotherapy (6). Compounds against novel epigenetic targets, such as Dot1L and Brd4, have been recently reported to effectively inhibit cancerous growth in mouse models (7–9). As such, a new battlefront for cancer treatment is emerging from studies of the epigenetic mechanisms underlying tumorigenesis, which bears promise for the identification of new drug targets and the development of additional pharmacological reagents.

Peptidylarginine deiminases (PADs) are a family of enzymes that can convert protein Arg residues to citrulline in a calcium- and sulfhydryl group-dependent manner. The PAD protein family in human and mouse contains five members, including PAD1–4 and PAD6, that show tissue and substrate specificity (10, 11). PAD1 is mainly expressed in the epidermal keratinocytes (57). PAD6 (also called ePAD) is a protein uniquely expressed in eggs and regulates the early stage of embryonic development, but it misses a conserved cysteine residue at the active center of all other PAD enzymes (12, 13). PAD2 is widely expressed in many tissues, including muscle, brain, and mammary gland, and is found to citrullinate myelin basic protein and actin (10, 11, 14). PAD4 is the only PAD family member containing a nuclear localization signal and citrullinates many sub-
strates including histones (e.g. H3, H2A, and H4), p300/CREB-binding protein (CBP), nucleophosmin, ING4, and nuclear lamin C to exert various functions (15–19). Genome-wide association and pathology studies have implicated PAD4 in the etiology of rheumatoid arthritis and cancers in human patients (20–23). We previously found that PAD4 functions as a corepressor of p53 and cooperates with a histone deacetylase HDAC2 to repress the expression of tumor suppressor genes (e.g. p21/CDKN1A and GADD45) (24, 25). Moreover, PAD4 was recently reported to cooperate with Elk-1 to facilitate c-fos expression. As such, PAD4 can positively and negatively regulate transcription in a promoter context-dependent manner (14, 24).

The tumor suppressor p53 protein functions as a central hub and key transcription factor of many cellular signaling pathways (26). In response to DNA damage, starvation, and stress signals, p53 regulates the expression of many genes that in turn relay the upstream signal to determine whether a cell undergoes cell cycle arrest, apoptosis, autophagy, etc. (27–30). Genome-wide mapping efforts have identified several hundred potential p53 target genes (31); many of these p53 target genes are effector proteins or proteins that regulate p53 functions in various positive and negative feedback loops (32). Sestrin 2 (SESN2) is a recently identified p53 target gene that regulates aging and induces autophagy by inhibiting the mTORC1 signaling pathway via the AMP-activated protein kinase (AMPK) and TSC1/2 signal cascade (33, 34). Interestingly, PAD4 was also recently identified as a p53 target gene, suggesting that PAD4 is a component of the intricate p53 signaling network (19, 35), suggesting that PAD4 likely regulates p53 function via a negative feedback loop.

Macroautophagy (hereafter referred as autophagy) is a catabolic cellular process wherein a large number of cytoplasmic components and organelles are engulfed by a membrane structure termed the phagophore to form autophagosomes, which in turn fuse with lysosomes to form autophagolysosomes for bulk degradation to remove damaged cellular organelles or regenerate metabolites during the cellular response to starvation (36–38). Autophagy is an important cellular process for organism health, and its deregulation has been linked with the progression of many human diseases, including neurodegenerative disorders and cancers (36, 39). Many autophagy regulatory factors are evolutionarily conserved from yeast to human, including the mammalian target of rapamycin (mTOR) Ser/Thr kinase-containing mTORC1 protein complex, which senses growth factors and nutrient abundance to control the rate of protein synthesis and the flux of autophagy (38, 40). The Yin-Yang balance of autophagy flux is key to maintaining the homeostasis between cell survival and cell death. The metabolites recycled through autophagy can sustain cell survival and contribute to chemotherapy resistance (41). On the other hand, under circumstances of excessive degradation of cellular components, autophagy can result in cell death (42). Therefore, both inducers and inhibitors of autophagy are of potential value for cancer treatment by regulating the autophagy flux rate.

Under physiological conditions, PAD4 is mainly expressed in peripheral blood neutrophils. We have previously found that PAD4 plays an antibacterial innate immune function through regulating the formation of neutrophil extracellular traps (43). On the other hand, PAD4 is markedly overexpressed in a majority of cancers of various tissue origins in pathology studies with a large cohort of human patient samples (21), suggesting that PAD4 may play a role in tumorigenesis. Currently, it remains unknown whether PAD4 can be pharmacologically targeted for cancer treatment. CI-amidine is a benzoyl-arginine-derived and mechanism-based pan PAD inhibitor that shows inhibitory effects to several PAD family members (44, 45). However, this compound causes cancer cell growth inhibition at ~150–200 μM concentration in cultured cells (24, 25). The relatively low potency of CI-amidine limits its preclinical exploration in cancer study and treatment. We have tested the idea that efficient small molecule PAD inhibitors can epigenetically activate tumor suppressor genes, thereby offering new avenues for cancer research and treatment. Our results showed that the lead compound YW3-56 activates a cohort of p53 target genes, including SESN2, which in turn inhibits the mTORC1 signaling pathway, thereby perturbing autophagy and inhibiting cancerous cell growth.

**EXPERIMENTAL PROCEDURES**

**Chemical Synthesis and Colorimetric Assays of PAD4 Inhibitors**—The method for chemical synthesis of novel PAD4 inhibitors was done largely following a method described previously (44). The colorimetric PAD4 assay method is described in detail in the supplemental material.

**Cell Culture and Treatment with Compounds and siRNA**—Human osteosarcoma U2OS and mouse sarcoma S-180 cells were purchased from ATCC and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a 5% CO₂ incubator. Early passage cells were used to minimize passage deviations. U2OS p53-shRNA and U2OS Ctrl-shRNA cells were generated essentially as described previously (25). Concentrations and duration of YW3-56 treatment were performed as specified in the figure legends and text of the current study. For the starvation assay, U2OS cells were first cultured in serum-free DMEM for 16 h and then in 10% fetal bovine serum, then different concentrations of YW3-56 were added back, and cells were further incubated for 8 h before additional analyses. SESN2 siRNA (Santa Cruz Biotechnology) and GFP siRNA (Dharmacon Inc.) were transfected into U2OS cells using the X-tremeGENE siRNA transfection reagents (Roche Applied Science). Cells were incubated in the presence of the siRNA for 48 h before adding YW3-56 and further incubated for 8 h before analyses.

**MTT and Flow Cytometry Assays**—Details of MTT and flow cytometry assays can be found in the supplemental material.

**Transmission Electron Microscopy and Phase Contrast Microscopy**—U2OS Cells were treated with 6 μM YW3-56 for 24 h and fixed in 2% glutaraldehyde in 0.1 M phosphate buffer, pH 7.4. Transmission electron microscopy analyses of U2OS cell morphology were performed using the service of the Penn State Electron Microscopy Facility. A VistaVision invert microscope (VWR International, LLC) equipped with a SPOT Insight digital camera (Diagnostic Instruments, Inc.) and a 10× phase
contrast lens were used to analyze cell growth and morphology in phase contrast microscopy analyses.

RNA Extraction, Microarray, Reverse Transcription, and Quantitative PCR—Details of these methods can be found in the supplemental material.

Western Blot and Fluorescent Imaging—Western blot and immunostaining were performed essentially as described previously (25). Antibodies used in Western blot were anti-p53 (Sigma, BP53-12), anti-PAD4 (custom-made), anti-H3Cit (Abcam, ab5103), anti-H3 (Abcam, ab1791), anti-p21 (Sigma, P1484), anti-PUMA (Calbiochem, PC665), anti-SESN2 (Abcam, ab57810), anti-p70S6K (Cell Signaling, 9202), anti-p70S6K-pT389 (Cell Signaling, 9205), anti-PCNA (Calbiochem, PC664), anti-PCNA-p36 (Cell Signaling, 2775), anti-p62/SQSTM1 (Bethyl Laboratories, A302-855A), and anti-β-actin (Sigma, A5458) at the appropriate dilutions. Anti-PCNA antibody (Cell Signaling, 2775) was used for immunostaining. DNA was stained by the DNA dye Hoechst. For subcellular localization of YW3-56, U2OS cells were treated with YW3-56 for 12 h and then fixed in 3.7% paraformaldehyde in PBS buffer containing 0.1% Triton X-100 and 0.2% Nonidet P-40, pH 7.4. Nuclear DNA was visualized by TOPRO3 staining and captured using an Olympus BX51 microscope at excitation 647 nm/emission 665 nm. Images of YW3-56 subcellular distribution were captured at excitation 359 nm/emission 461 nm.

Chromatin Immunoprecipitation (ChIP) Assay—ChIP experiments were carried out essentially as described previously (14). Antibodies used in ChIP were: anti-p53 (Sigma, BP53-12), anti-PAD4 (custom-made), anti-H3Cit (Abcam, ab5103), and anti-H3R17Me (Abcam, ab8284). Primers used in quantitative ChIP-qPCR for +733 are listed in supplemental Table S2. Other primers are available upon request.

In Vivo Antitumor Assay—S-180 ascites tumor cells were used to form solid tumors after subcutaneous injection essentially as described previously (46). More details are available in the supplemental material. All animal experiments were approved by the Institutional Animal Care and Use Committee of Capital Medical University and performed by accepted veterinary standards.

RESULTS

Novel PAD Inhibitors with Increased Ability to Inhibit PAD4 and Cancer Cell Growth—To develop more potent inhibitors for PAD4 inhibition and cancer cell killing, we carried out an extensive structure-and-activity relationship study based on the Cl-amidine blueprint (Fig. 1A). The Nα and Cα of the ornithine backbone were engineered with different structural motifs or tethered within a ring scaffold via the standard amide-ester-coupling chemistry to generate 23 new compounds in four synthesis, evaluation, and redesign cycles (supplemental Fig. S1). Cl-amidine is a very hydroscopic compound, which readily dissolves in water-based solutions and likely has low cell membrane permeation ability. Therefore, one of the design schemes was to optimize the hydrophobicity and bioavailability of the new compounds. The 23 compounds were first used at 20 μM to measure their cell-killing efficacy in osteosarcoma U2OS cells by MTT assays (supplemental Fig. S2). Several potent inhibitors (e.g. YW3-56, YW4-03, and YW4-15) were selected to measure their IC50 in cell killing by MTT assays and PAD4 inhibition by a colorimetric method (47) (supplemental Fig. S3). Inhibitors with low micromolar IC50 values, including YW4-03 and YW3-56, were successfully developed (Fig. 1B).

When compared with Cl-amidine, YW3-56 showed >60-fold increase in cell growth inhibition efficacy (IC50 about 2.5 μM) but only ~5-fold increase in PAD4 inhibition (IC50 about 1–5 μM) (Fig. 1B). We postulated that the dimethyl-amide-naphthalene moiety at the Nα position and a phenyl ring at the Cα position increase the hydrophobicity of YW3-56, thereby enhancing its membrane permeability and cancer cell killing. To test this idea, flow cytometry analyses were performed to evaluate cellular uptake of YW3-56 using the intrinsic fluorescent signal generated by the naphthalene moiety in YW3-56 (Fig. 1C). Fluorescent signals were greatly increased in all cells after YW3-56 treatment when compared with untreated cells (Fig. 1C). To further test the importance of membrane permeation in cell killing, a bulky and hydrophilic biotin moiety was added on the para position of the Cα benzyl ring of YW3-56 to generate YW4-15. This biotin moiety greatly decreased the cellular uptake of YW4-15 in flow cytometry analyses (Fig. 1C). As a consequence of poor membrane penetration, although YW4-15 has a PAD4 inhibition efficacy similar to YW3-56, its cancer cell killing ability was greatly decreased when compared with YW3-56 (Fig. 1B). Taken together, the above results indicate that YW3-56 has an improved efficacy in PAD4 inhibition and cell membrane penetration and thereby kills cancer cells with high efficacy.

Based on the above results, we chose YW3-56 as the lead compound for further detailed biological analyses. Taking advantage of the fluorescent naphthalene moiety, we analyzed the subcellular distribution of YW3-56 and found that it is mainly concentrated in the nucleus, with a certain degree of enrichment in the nucleolus to form punctate structures (Fig. 2A). Because PAD4 is a nuclear protein, the nuclear localization of YW3-56 indicates that it is in the same subcellular compartment as PAD4. The nucleolar localization of YW3-56 is notable given that nucleophosmin, an abundant protein in the nucleolus, is a known substrate of PAD4 (35, 48). Furthermore, we analyzed the dose-dependent effects of YW3-56 on cell morphology and growth. At 2–4 μM concentrations, YW3-56 displayed mainly cytostatic effects by slowing cell division, whereas at higher concentrations, it exerted cytotoxic effects by altering cell morphology and killing cells (supplemental Fig. S4). Recently, PAD4 and to a lesser extent PAD2, but not PAD3, were reported to citrullinate histone H3 (11). Given our interest in understanding histone citrullination in gene regulation, we next evaluated the target specificity of YW3-56 to PAD4 and PAD2 using histone H3 as a substrate. Consistent with the previous study (11), PAD2 had a weaker activity toward histone H3 when compared with PAD4 (Fig. 2B). On the other hand, using histone H3 as a substrate, the IC50 of YW3-56 in PAD4 inhibition is about 1–2 μM, whereas its IC50 in PAD2 inhibition is about 0.5–1 μM (Fig. 2C). Due to its inhibitory activity to PAD2, YW3-56 is referred to as a PAD inhibitor hereafter.

YW3-56 Induces p53 Target Genes and Regulators of mTORC1—To analyze the molecular mechanisms by which YW3-56 induces cancer growth inhibition, we performed
microarray analyses using Affymetrix microarray chips. Using a 1.5-fold change as the cutoff \((n = 3, \text{false discovery rate} < 0.05)\), 843 genes were induced, whereas 646 genes were repressed after YW3-56 treatment in U2OS cells. Gene ontology analyses found that the cell cycle, nucleosome assembly, gene regulation, and cell death pathway genes were significantly enriched (Fig. 3A). Within the group of genes of the nucleosome assembly pathway, the expression of multiple histone genes was decreased by severalfold (supplemental Fig. S5, A and B). The decreased histone gene expression was further analyzed using reverse transcription quantitative PCR (RT-qPCR) to corroborate the microarray results (supplemental Fig. S5C). Both microarray and RT-qPCR assays detected a significant decrease of histone genes, suggesting that YW3-56 can impact on the cell cycle progression by inhibiting histone gene expression via mechanisms yet to be characterized in future research. More-

---

**FIGURE 1. Synthesis and characterization of more potent PAD4 inhibitors.** A, structures of PAD4 inhibitors, including the prototype inhibitor Cl-amidine (upper left panel), the generic structure for medicinal chemistry modification (upper middle panel), the new compound YW4-03 (upper right panel), the lead compound YW3-56, and its biotin-conjugated form YW4-15. YW3-56 and YW4-15 are intrinsically fluorescent molecules because of the dimethyl-amide-naphthalene moiety. B, tabulation of the IC50 values of cell growth and PAD4 inhibition by several representative inhibitors. IC50 for PAD4 inhibition was measured using colorimetric assays. IC50 for cell growth inhibition was measured by MTT assays in the above three independent experiments. C, flow cytometry assays to measure the accumulation of YW3-56 and its biotin-conjugated form YW4-15 after 10 \(\mu M\) of compound treatment for 12 h (a representative result of three repeats is shown).
over, because PAD4 regulates the expression of p53 target genes (24, 25), we compared our microarray gene list with the 122 direct p53 target genes reported previously (31). 14 genes identified in the microarray analyses overlap with the p53 target genes, representing a significant enrichment of p53 genes (14/122, p < 0.01) (Fig. 3A). To show the consistency of the three independent microarray experiments, heat maps of 356 genes showing an average of ≥2-fold increase and 227 genes showing an average ≥2-fold decrease are presented (Fig. 3B). In contrast to the primary decrease in histone gene expression, genes of the p53 pathway were mainly up-regulated after YW3-56 treatment (supplemental Table S1). Notably, two upstream regulators of the mTOR signaling pathway, REDD1 (also called REDD1), were induced 6.1- and 4.2-fold, respectively, after YW3-56 treatment (supplemental Table S1). The expression of mTOR regulator SESN2 but not AMPK was increased after YW3-56 treatment in a p53-dependent manner, suggesting that YW3-56 specifically activates a subset of mTOR regulatory genes (Fig. 4A). Moreover, the relatively less potent inhibitors YW3-88 and BL1-07 induced the expression of p53 target genes, including SESN2, at higher concentrations, suggesting that multiple PAD inhibitors can exert similar effects on gene activation in U2OS cells (supplemental Fig. S7).

PAD4 Serves as a Corepressor of p53 to Directly Regulate SESN2 Expression—To analyze whether YW3-56 primarily targets PAD4 to exert its effects on histone citrullination and SESN2 expression, we treated U2OS cells with YW3-56 and PAD4 siRNA. Both YW3-56 treatment and siRNA depletion of PAD4 activated SESN2 expression and decreased histone H3 citrullination (Fig. 4B), suggesting that PAD4 plays a direct role in regulating SESN2 expression. Moreover, depletion of PAD4 sensitizes cell responses to YW3-56 treatment, showing a further decrease in histone H3 citrullination and increase in SESN2 expression (Fig. 4B). Although YW3-56 was found to inhibit PAD2 and PAD4, the histone H3 citrullination activity of PAD2 is much weaker in vitro (Fig. 2C), and PAD2 preferentially localizes to the cytoplasm (50). The above results indicate that PAD4 is the main enzyme responsible for histone H3 citrullination and a main target of YW3-56 in regulating the SESN2 expression. On the other hand, it remains possible that YW3-56 impacts on PAD2 in other aspects of its anticancer activity.

Although SESN2 was reported as a p53 target gene, the direct evidence for p53 binding on a specific region of the SESN2 promoter is not available according to our knowledge. To map p53 binding site(s) at the SESN2 gene, we performed ChIP experiments using a set of primers spanning regions of the SESN2 gene with putative p53 binding consensus sites predicted by the PROMO program (Fig. 4C). The binding of p53 to the +733 position of SESN2 was increased ~8-fold after UV irradiation treatment in U2OS cells (Fig. 4D), suggesting that this region contains putative p53 binding sites. Moreover, p53 binding at the +733 position of SESN2 was increased >4-fold with a concomitant increase of histone H3 Arg-17 methylation (H3R17Me) after YW3-56 treatment (Fig. 4E). In contrast, a decrease in PAD4 binding and histone H3 citrullination (H3Cit) at the +733 position was detected after YW3-56 treatment (Fig. 4E). The above results support a model in which PAD4 serves as a corepressor of p53 to repress SESN2 expression in untreated cells. In contrast, after YW3-56 treatment, p53 associates, whereas PAD4 dissociates from, the SESN2

**FIGURE 2. Subcellular localization of YW3-56 and its inhibition of PAD4 and PAD2 activity.** A, upon the addition of YW3-56 to U2OS cells, the subcellular localization of YW3-56 (green color) was visualized by fluorescent microscope. B, comparison of the GST-PAD4 and GST-PAD2 activity using histone H3 substrate in Western blot (WB) experiments. C, different amounts of YW3-56 were preincubated with PAD2 and PAD4. Enzymatic activity toward histone H3 substrate after inhibitor incubation was detected by Western blot experiments. The total amount of H3 was probed with a general histone H3 antibody. Representative results of over three repeats experiments are shown in panels A–C.
Role of SESN2 in YW3-56-mediated Inhibition of the mTORC1 Signaling—SESN2 is induced by starvation and stress conditions and serves as an upstream inhibitor of mTORC1 by forming a complex with TSC1/2 (33). mTORC1 inhibition decreases its phosphorylation of p70S6K and 4E-BP1, thereby inhibiting translation, cell growth, and proliferation, whereas accelerating autophagy (17, 18) (illustrated in Fig. 5A). Next, we analyzed whether YW3-56 inhibits the mTORC1 signaling cascade by SESN2 induction. The amount of SESN2 protein was increased by YW3-56 in U2OS cells treated with control shRNA (Fig. 5B, lanes 1–4). In contrast, depletion of p53 by shRNA decreased the basal level of SESN2 and its induced levels after YW3-56 treatment (Fig. 5B, lanes 5–8), indicating that p53 is important for the relative levels of SESN2 expression. It is noteworthy that SESN2 expression can be induced at higher YW3-56 concentrations (Fig. 5B, lane 8), suggesting that a low level of p53 in p53-depleted U2OS cells is sufficient for YW3-56-mediated SESN2 induction. Although the amount of p70S6K protein was not altered in U2OS cells treated with YW3-56 at different concentrations (Fig. 5B, lanes 1–4), the depletion of p53 decreased the amount of p70S6K protein regardless of inhibitor treatment (Fig. 5B, lanes 5–8). In agreement with the inhibitory role of SESN2 in the SESN2-TSC1/2-mTORC1 signaling axis, the induction of SESN2 by YW3-56 occurred with a concomitant decrease in p70S6K phosphorylation at Thr-389 (Fig. 5B). Furthermore, the inhibitory effects of YW3-56 on histone H3 citrullination were detected in U2OS cells treated with the control or the p53 shRNA (Fig. 5B). To test whether YW3-56 induces SESN2 and inhibits mTOR under stress conditions, we treated serum-starved U2OS cells with YW3-56 or a combination of YW3-56 and serum. Under serum starvation and serum stimulation conditions, YW3-56 treatment induced SESN2 expression and dramatically decreased the phosphorylation of p70S6K as well as another mTORC1 target protein 4E-BP1 (Fig. 5C). The phosphorylation of 4E-BP1 plays an important role in translation by regulating its binding to the translation initiation factor eIF-4E (40, 51). To further assess the role of SESN2 in YW3-56-mediated mTORC1 inhibition, we used siRNAs to deplete SESN2 in U2OS cells. Depletion of SESN2 slightly increased p70S6K protein levels but drastically increased its phosphorylation levels (Fig. 5D, lane 3 as compared with lane 1), suggesting that SESN2 is important for regulating p70S6K phosphorylation in cells without YW3-56 treatment. On the other hand, YW3-56 dramatically decreased p70S6K phosphorylation in cells treated with the control GFP siRNA (Fig. 5D, lane 2 as com-
pared with lane 1), whereas p70S6K phosphorylation was only slightly decreased after YW3-56 treatment in SESN2 depletion cells (Fig. 5D, lane 4 as compared with lane 3), suggesting that SESN2 is important for YW3-56-mediated inhibition of p70S6K phosphorylation. Taken together, the above results indicate that YW3-56 treatment can induce the expression of SESN2, which in turn triggers a cascade of signaling events to inhibit the mTORC1 kinase activity.

YW3-56 Regulates the Autophagy Flux—The induction of upstream inhibitors of the mTORC1 pathway, which keeps the Yin-Yang balance of translation and autophagy, prompted us to analyze whether YW3-56 treatment regulates autophagy in U2OS cells. In transmission electron microscopy (TEM) analyses, many large vesicles containing engulfed and digested membrane and organelle structures were observed in YW3-56-treated cells but not in control cells (Fig. 6A and supplemental Fig. S8). These large vesicular structures (denoted by red arrows) have structural characteristics of autophagic vesicles (e.g. autophagosomes and autophagolysosomes) (52). The formation of phagophores and autophagosomes is associated with lipidation of LC3-I with phosphatidylethanolamine to produce the membrane-associated LC3-II protein (52). Consistent with autophagic vesicle accumulation, LC3-II accumulated after YW3-56 treatment in a drug dose-dependent manner (Fig. 6B). Furthermore, LC3 staining was detected in multiple large punctate structures in U2OS cells after YW3-56 treatment but not in control cells (Fig. 6C), offering additional evidence for the formation of autophagosomes and/or autophagolysosomes after YW3-56 treatment.

The flux rate of autophagy can be controlled by several steps: 1) the enclosure of cytoplasmic components by phagophores to form autophagosomes; 2) the fusion of autophagosomes with lysosomes to form autophagolysosomes; 3) the dissolution of autophagolysosomes (illustrated in Fig. 6D). To analyze how YW3-56 affects the stepwise progression of autophagy, we performed live cell imaging using an mCherry-GFP-LC3 reporter construct. The GFP signal in the mCherry-GFP-LC3 fusion protein is quenched under acidic pH in autophagolysosomes,
making it a nice fluorescent sensor to simultaneously analyze autophagosomes and autophagolysosomes (52, 53). We found that ectopically expressed mCherry-GFP-LC3 was detected as predominantly red and dynamically moving spots with yellow spots occasionally observed in control U2OS cells, suggesting that the reporter protein was mainly associated with autophagolysosomes (Fig. 6E and supplemental Video S1). In contrast, after treatment with YW3-56, enlarged red and yellow speckles with reduced movement were observed in cells remaining attached to the culture surface (Fig. 6F and supplemental Video S2) and in moribund cells that were shrinking in size and partially losing their attachment with the culture surface (Fig. 6G and supplemental Video S3), indicating that both autophagosomes and autophagolysosomes were accumulated after YW3-56 treatment. Due to its selective degradation during autophagy, p62 (also called sequestosome 1, SQSTM1) serves as a marker for autophagy, and its cellular level inversely correlates with the rate of autophagic vesicle degradation (52). We found that p62 dramatically accumulated in YW3-56-treated cells in a dose-dependent manner (Fig. 6B), suggesting that YW3-56 regulates the autophagy flux by inhibiting autophagic vesicle breakdown by lysosomes. Two scenarios may lead to the accumulation of autolysosomes: first, an increase in the influx rate with more autophagosome feeding into the autophagy process; and second, a decrease in the efflux rate with the less efficient fusion of autophagosomes with lysosomes and subsequent autophagolysosome dissolution. Note that these two possible mechanisms are not mutually exclusive and can function independently or in combination. Our results suggest that YW3-56 may induce the accumulation of autophagosomes by inhibiting mTORC1 as well as inhibiting autophagosome degradation to slow down the autophagy flux rate.

YW3-56 Effectively Inhibits Cancer Growth in Mouse Sarcoma S-180 Xenograft Model—To test the effects of YW3-56 on tumor growth in mice, we applied a well established mouse sarcoma S-180 cell-derived tumor model (54). MTT assays showed that YW3-56 inhibited S-180 cell growth with an IC50 of $10^{-15}$ M (Fig. 7A). RT-qPCR analyses showed that YW3-56 treatment induced the expression of p53 and its target genes, including SESN2, in a concentration-dependent manner (Fig. 7B). Upon intraperitoneal injection of YW3-56 at a concentration of 10 mg/kg of mouse body weight daily for 1 week, the growth of S-180 tumor was decreased to 51.5% of that of the control group injected with an isotonic saline solution (Fig. 7, C and D). The HDAC inhibitor SAHA (also called vorinostat) is a United States Food and Drug Administration-approved drug for treatment of cutaneous T cell lymphoma. As a reference to evaluate the effect of YW3-56, we injected SAHA at 5
mg/kg of body weight concentration daily for 1 week and found that S-180-derived tumor growth was decreased to 44.6% of that of the control group (Fig. 7, C and D). As such, YW3-56 showed a similar tumor growth inhibition effect as that of SAHA under the conditions applied. Additionally, because we have found that PAD4 coordinates with HDAC2 in repressing p53 target gene expression (25), we tested the synergy of the PAD4 inhibitor and HDAC inhibitor in tumor growth. We found that after injection of a mix of YW3-56 and SAHA at half of their concentrations when applied singularly, tumor growth was decreased to 27.1% of that of the control group (Fig. 7, C and D), suggesting an additive effect of the two inhibitors. In contrast, the size of the spleen was decreased to 50% of that of control mice after doxorubicin treatment (supplemental Fig. S9), suggesting that inhibitors targeting PAD4 and HDACs are less toxic when compared with doxorubicin. Additionally, we performed a 3-month YW3-56 treatment experiment with a daily injection of YW3-56 at 10 mg/kg of body weight in a pair of nude mice and determined that the sizes of the mouse body and vital organs were not altered after YW3-56 treatment.

**DISCUSSION**

An emerging theme in the field of cancer research is that the epigenetic silencing of tumor suppressor genes can lead to increased cell growth and cell division during tumorigenesis. Because epigenetic alterations do not include mutations in DNA *per se*, tumor suppressor genes can be turned back on by

---

**FIGURE 6. YW3-56 induces autophagy in human osteosarcoma U2OS cells.** A, transmission electron microscopy images of mock-treated cells at low magnification (Low mag.) and high magnification (High mag.) as well as YW3-56-treated cells (lower panels). Distinctive structures with characteristics of autophagolysosomes in YW3-56-treated cells are denoted by red arrows. Scale bars are 1 μm. B, levels of LC3-I and LC3-II as well as p62/SQSTM1 were analyzed by Western blot after different doses of YW3-56 treatment for 12 h. C, LC3 was detected in large speckles denoted by white arrows in U2OS cells after YW3-56 treatment (lower panels) but not in control cells (upper panels). D, schematic drawing of the autophagy process. The mCherry-GFP-LC3-PE reporter is red and green when it associates with phagophores (also called isolation membranes) and autophagosomes (PE denotes phosphatidylethanolamine). After fusion with lysosomes to form autophagolysosomes, the GFP signal is quenched by the acidic condition. E, a representative microscopy image showing red-colored autophagolysosomes and red and green double-colored autophagosomes in control mock-treated cells. See video S1 for more details. F, a representative microscopy image showing red-colored autophagolysosomes and red and green double-colored autophagosomes in YW3-56-treated cells with slight morphology changes. See video S2 for more details. G, a representative microscopy image showing red-colored autophagolysosomes and red and green double-colored autophagosomes in a moribund cell after YW3-56 treatment. Insets show details of the structures at higher magnification. See video S3 for more details. Arrowheads denote autophagolysosomes, and arrows denote autophagosomes (E–G). Scale bars in panels E–G represent 5 μm.
targeting epigenetic modifiers, as evidenced by recent progression in this area (3–5). Previous pathological and genetic studies have linked PAD4 and protein Arg citrullination with several human diseases, including cancers and autoimmune disorders. In cancer cells, a fine-tuned increase of PAD4 protein represses the expression of p53 target genes, such as p21/CDKN1A, GADD45, and PUMA. Here, using the newly developed PAD inhibitors, we identified a novel molecular mechanism by which PAD4 represses the expression of the p53 target gene SESN2 to promote cancer cell growth, suggesting that PAD4 may facilitate tumorigenesis from multiple aspects. The lead compound YW3-56 demonstrates tumor growth inhibition effects singularly or in combination with SAHA, whereas it has little if any detectable side effects under the conditions applied. Given that PAD4 is overexpressed in the majority of human cancers of many tissue origins and that its levels are elevated in the blood of cancer patients (21), further investigation of PAD4 and its inhibitors is of important value in cancer diagnosis and treatment.

Cancer cells respond very fast to YW3-56 treatment. As quick as 6 h after YW3-56 addition to U2OS cells, we observed changes in cell morphology, such as a loss of cell attachment and formation of cytosolic bubbles. This fast kinetics is in agreement with the high membrane permeability and accumulation in cancer cells detected by flow cytometry analyses as well as the immediate induction of the SESN2 and DDIT4 gene expression within hours after the drug treatment. Autophagy represents an important cellular adaptation response to various stress signals (37, 38, 52). Starvation leads to the activation of several signaling pathways including the p53-SESN2 axis. Once expressed, SESN2 can work together with the TSC1-TSC2 protein complex to inhibit the mTORC1 complex-mediated phosphorylation of its target proteins that are involved in protein synthesis. The decreased rate of protein translation is coupled with a concomitant increase of cellular autophagy. Our siRNA results showed that SESN2 is directly regulated by PAD4 and is a sufficient factor for regulating the phosphorylation of mTORC1 substrate p70S6K. YW3-56 activates the expression of SESN2 and inhibits the phosphorylation of p70S6K, offering a mechanism by which YW3-56 may induce autophagy. Moreover, YW3-56 treatment leads to the accumulation of both autophagosomes and autophagolysosomes as well as the accumu-
mulation of p62/SQSTM1, suggesting that it exacerbates the autophagy burden by inhibiting autophagic vesicle degradation. Our ongoing research will further unveil the molecular and cellular mechanisms underlying the YW3-56 activity to curb cancer cell growth.

Cl-amidine was originally designed as a structural mimic of the PAD substrate peptidylarginine by the Thompson group (44). Cl-amidine shows a broad inhibition of all active PAD family members, albeit at different efficiency (PAD1 > PAD4 > PAD3 > PAD2) (45). Our work has found that Cl-amidine exerts 50% tumor growth inhibition at ~150–200 μM concentrations (24). In this study, we developed a set of novel PAD inhibitors by an extensive structure-and-activity relationship study based on the chloroacetamidine functional group, which covalently modifies the active center cysteine of the PAD enzymes (44). The lead compound YW3-56 inhibits cancer cell growth at low micromolar concentrations, showing >60-fold increase in cancer growth inhibition over Cl-amidine. This gain in YW3-56 inhibitor efficacy is due to two possible factors: 1) a mild increase in PAD4 inhibition achieved by optimizing the backbone; and 2) a large increase in the membrane permeability of YW3-56 by the addition of a more hydrophobic dimethyl-amide-naphthalene moiety at the Nα position and a phenyl ring at the Cα position. In parallel to our study, the Thompson group (45, 55) has recently reported two additional structures related to Cl-amidine by adding one or two amino acids to the Nα position of Cl-amidine. Given that these inhibitors are all developed on a mechanism-based design, they need to compete with the in vivo PAD substrates to achieve efficient inhibition. Allosteric effect inhibition may represent a future strategy to develop additional inhibitors. On the other hand, the current experimental data found that mechanism-based PAD inhibitors derived from the Cl-amidine backbone show pharmacological efficacy both in cell culture and in mouse models, suggesting that this strategy may prove to be viable in future pharmacology exploration.

The PAD family of contains five members in human and mouse, including PAD1–4 and PAD6, that show tissue and substrate specificity (56, 57). A recent study with PAD2, PAD3, and PAD4 enzymes found that PAD4 prefers histone H3, whereas PAD2 prefers actin for citrullination (11). However, the interaction of PAD4 with its substrate peptides is mainly mediated by the peptide backbone (58), suggesting that PAD4 may target Arg residues embedded in a diverse range of substrates. To date, histones H3, H4, and H2A, ING4, nucleophosmin, and nuclear lamin C have been identified as substrate of PAD4. This imposes a future challenge in addressing the function of PAD4 in targeting these particular substrates. On the other hand, the loose substrate context dependence of PAD proteins likely imposes additional challenges to developing isoform-specific PAD inhibitors for biology and preclinical studies. The lead compound YW3-56 can inhibit both PAD2 and PAD4. At the current stage of our inhibitor and drug development, the broad inhibition of YW3-56 to PAD enzymes should not be a concern for clinical application given that many effective cancer therapies target general cellular processes and successful epigenetic inhibitors used in cancer therapy often target a family of enzymes, such as the DNA methyltransferase inhibitors and the histone deacetylase inhibitors.

Acknowledgments—We thank members of the Chen and Wang groups as well as the Center for Eukaryotic Gene Regulation for helpful discussions and comments and Sarah L. Moore for editing the manuscript. We thank Drs. Siqi Peng and Ming Zhao at Capital Medical University, Beijing, China for support and comments on the work. The mCherry-GFP-LC3 is a generous gift from Dr. Terje Johansen. We thank Dr. Tso-Pang Yao for reagents. We thank the Penn State University (PSU) Microscopy and Cytometry Facility and the Genomics Core Facility for technical help. A patent application based on this work was submitted.

Addendum—In the first paragraph under “Experimental Procedures” of the online published manuscript, we cited Ref. 44 (Luo et al., Biochemistry, 2006), the original paper that developed the synthesis method of Cl-amidine by Dr. Thompson’s group. However, because we used a solution-based synthesis scheme to generate PAD inhibitors in our study, the paper published by the Thompson group (Causey and Thompson, Tetrahedron Letters, 2008) describing the solution phase synthesis of Cl-amidine should be a more appropriate reference (59) to be cited in addition to Ref. 44.

REFERENCES

1. Li, B., Carey, M., and Workman, J. L. (2007) The role of chromatin during transcription. Cell 128, 707–719
2. Conaway, J. W. (2012) Introduction to theme “chromatin, epigenetics, and transcription.” Annu. Rev. Biochem. 81, 61–64
3. Chi, P., Allis, C. D., and Wang, G. G. (2010) Covalent histone modifications: miswritten, misinterpreted, and mis-erased in human cancers. Nat. Rev. Cancer 10, 457–469
4. Sandoval, J., and Esteller, M. (2012) Cancer epigenomics: beyond genomics. Curr. Opin. Genet. Dev. 22, 50–55
5. Wang, G. G., and Allis, C. D. (2009) “Misinterpretation” of a histone mark is linked to aberrant stem cells and cancer development. Cell Cycle 8, 1982–1983
6. Yoo, C. B., and Jones, P. A. (2006) Epigenetic therapy of cancer: past, present, and future. Nat. Rev. Drug Discov. 5, 37–50
7. Daigle, S. R., Olhava, E. J., Therke, K. C., Majer, C. R., Sneeringer, C. J., Song, J., Johnston, L. D., Scott, M. P., Smith, J. J., Xiao, Y., Jin, L., Kunz, K. W., Cheshworth, R., Moyer, M. P., Bernt, K. M., Tseng, J. C., Kung, A. L., Armstrong, S. A., Copeland, R. A., Richon, V. M., and Pollock, R. M. (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65
8. Delmore, J. E., Issa, G. C., Lemieux, M. E., Rahl, P. B., Shi, J., Jacobs, H. M., Kastritis, E., Gilpatrick, T., Paranal, R. M., Qi, J., Chesi, M., Schinzel, A. C., McKeown, M. R., Heffernan, T. P., Vakoc, C. R., Bergsagel, P. L., Ghobrial, I. M., Richardson, P. G., Young, R. A., Hahn, W. C., Anderson, K. C., Kung, A. L., Bradner, J. E., and Mitsiades, C. S. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917
9. Zubr, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sisinni, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., Taylor, M. J., Johns, C., Chicas, A., Mulloy, J. C., Kogan, S. C., Brown, P., Valient, P., Bradner, J. E., Lowe, S. W., and Vakoc, C. R. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukemia. Nature 478, 524–528
10. Vossenaar, E. R., Zandman, A. I., van Venrooij, W. J., and Pruijn, G. J. (2003) PAD, a growing family of citrullinating enzymes: genes, features, and involvement in disease. Biochimie 85, 1106–1118
11. Darrah, E., Rosen, A., Giles, J. T., and Andrade, F. (2012) Peptidylarginine deiminase 2, 3, and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann. Rheum. Dis. 71, 92–98
12. Wright, P. W., Bolling, L. C., Calvert, M. E., Sarmento, O. F., Berkeley, E. V., Shea, M. C., Hao, Z., Jayes, F. C., Bush, L. A., Shetty, J., Shore, A. N.
lian autophagy research. Cell 140, 313–326
53. Bjørkøy, G., Lamark, T., Brech, A., Outzen, H., Perander, M., Overvatn, A., Stenmark, H., and Johansen, T. (2005) p62/SQSTM1 forms protein aggre-
gates degraded by autophagy and has a protective effect on huntingtin-
induced cell death. J. Cell Biol. 171, 603–614
54. Alfaro, G., Lomeli, C., Ocadiz, R., Ortega, V., Barrera, R., Ramirez, M., and Nava, G. (1992) Immunologic and genetic characterization of S180, a cell
line of murine origin capable of growing in different inbred strains of mice. Vet Immunol. Immunopathol. 30, 385–398
55. Causey, C. P., Jones, J. E., Slack, J. L., Kamei, D., Jones, L. E., Subrama-
nian, V., Knuckley, B., Ebrahimi, P., Chumanevich, A. A., Luo, Y., Hashimoto, H., Sato, M., Hofseth, L. J., and Thompson, P. R. (2011) The development of N-α-(2-carboxyl)benzoyl-N⁵-(2-fluoro-1-imino-
ethyl)-l-ornithine amide (α-F-amidine) and N-α-(2-carboxyl)benzoyl-
N⁵-(2-chloro-1-iminoethyl)-l-ornithine amide (α-Cl-amidine) as sec-
ond generation protein arginine deiminase (PAD) inhibitors. J. Med.
Chem. 54, 6919–6935
56. Vossenaar, E. R., Radstake, T. R., van der Heijden, A., van Mansum, M. A., Dieteren, C., de Rooij, D. J., Barrera, P., Zendman, A. J., and van Venrooij, W. J. (2004) Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 63,
373–381
57. Ying, S., Dong, S., Kawada, A., Kojima, T., Chavanas, S., Méchin, M. C., Adoue, V., Serre, G., Simon, M., and Takahara, H. (2009) Transcriptional
regulation of peptidylarginine deiminase expression in human keratino-
cytes. J. Dermatol. Sci. 53, 2–9
58. Arita, K., Shimizu, T., Hashimoto, H., Hidaka, Y., Yamada, M., and Sato, M. (2006) Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc. Natl. Acad. Sci. U.S.A. 103, 5291–5296
59. Causey, C. P., and Thompson, P. R. (2008) An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4
(PAD4). Tetrahedron Lett. 49, 4383–4385